title: Prognostic analysis of ovarian cancer associated with endometriosis.
abstract: OBJECTIVE
  The objective of the study was to evaluate the prognosis of ovarian cancer arising in endometriosis.
  
  
  METHODS
  We retrospectively compared 42 cases of endometriosis-associated ovarian cancer (EAOC) with 184 cases of ovarian carcinoma without endometriosis (OC).
  
  
  RESULTS
  The median age in the EAOC group was 52 vs 59 years in OC (P < .05). In comparison with OC, the EAOC patients were more likely to have low-grade (21% vs 8%; P = .04) and early-stage tumors (International Federation of Gynecology and Obstetrics I and II combined) (49% vs 24%; P = .002). Clear cell (21% vs 2%) and endometrioid (14% vs 3%) tumors were more frequent in EAOC, whereas mucinous tumors were more prevalent in OC (P = .001). The median survival (199 vs 62 months) and the 5 year survival (62% vs 51%) were better for EAOC when compared with OC (P = .038). After controlling for age, stage, grade, and treatment, association with endometriosis was not an independent predictor of better survival in ovarian cancer.
  
  
  CONCLUSIONS
  As such, EAOC has a much better survival rate than OC. This could be explained by the higher prevalence of early-stage and low-grade tumors in EAOC when compared with OC.
authors.affiliation: Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Kumar
authors.forename: Adnan
authors.initials: A
authors.lastname: Munkarah
authors.forename: Haitham
authors.initials: H
authors.lastname: Arabi
authors.forename: Sudeshna
authors.initials: S
authors.lastname: Bandyopadhyay
authors.forename: Assaad
authors.initials: A
authors.lastname: Semaan
authors.forename: Kinda
authors.initials: K
authors.lastname: Hayek
authors.forename: Gunjal
authors.initials: G
authors.lastname: Garg
authors.forename: Robert
authors.initials: R
authors.lastname: Morris
authors.forename: Rouba
authors.initials: R
authors.lastname: Ali-Fehmi
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000401:mortality / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000473:pathology; D004715:Endometriosis / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate